Skip to search formSkip to main contentSkip to account menu

EMD1214063

Known as: EMD 1214063, EMD-1214063 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

PyridazinesPyrimidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
The hepatocyte growth factor receptor as a potential therapeutic target for dedifferentiated liposarcoma
Dedifferentiated liposarcomas (DDLPS) are highly resistant to conventional chemo- and radiotherapies, with surgical resection… 
2014
2014
ET-28COMBINATION THERAPY WITH MET TYROSINE KINASE INHIBITOR EMD1214063 AND BEVACIZUMAB
INTRODUCTION: EMD1214063 is a MET tyrosine kinase inhibitor with the potential for antineoplastic activity. Selectively binding… 
2014
2014
Abstract 3691: Met target inhibition-guided efficacy in preclinical models
Background: A direct comparison of drug efficacy for the multiple agents currently in clinical development targeting MET-driven… 
2014
2014
Abstract 1690: Attacking EGFR mutant lung cancer by combined EGFR and c-Met inhibition
In lung adenocarcinomas, targeted therapy with the EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib is associated… 
2013
2013
Abstract 4435: Targeting Met signaling to overcome human cancer cell resistance to radiation.
Purpose: Targeting signaling pathways that are implicated in cancer cell resistance to therapy are being investigated to improve… 
2012
2012
Abstract 1787: The c-Met inhibitors EMD 1214063 and EMD 1204831 are effective in combination with EGFR and VEGF inhibitors in NSCLC models
c-Met is a receptor tyrosine kinase that has hepatocyte growth factor as its ligand. Evidence from biochemical and human genetic… 
2010
2010
Abstract 5777: EMD 1214063, an exquisitely selective c-Met kinase inhibitor in clinical phase 1
The role of the receptor tyrosin kinase c-Met in tumor progression, metastasis and aggressiveness has been convincingly… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)